Upadhyay S.K.
62
Coauthors
7
Documentos
Volumen de publicaciones por año
Cargando gráfico
| Año de publicación | Num. Publicaciones |
|---|---|
| 2014 | 1 |
| 2015 | 1 |
| 2016 | 2 |
| 2017 | 2 |
| 2018 | 1 |
Publicaciones por áreas de conocimiento
Cargando gráfico
| Área de conocimiento | Num. Publicaciones |
|---|---|
| Cáncer | 6 |
| Bioquímica | 5 |
| Farmacología | 2 |
| Descubrimiento de fármacos | 2 |
| Química analítica | 1 |
Publicaciones por áreas temáticas
Cargando gráfico
| Área temática | Num. Publicaciones |
|---|---|
| Farmacología y terapéutica | 4 |
| Enfermedades | 4 |
| Bioquímica | 2 |
| Fisiología humana | 2 |
| Química analítica | 1 |
Principales fuentes de datos
| Origen | Num. Publicaciones |
|---|---|
| Scopus | 7 |
| Google Scholar | 0 |
| RRAAE | 0 |
Cargando gráfico
Coautores destacados por número de publicaciones
| Coautor | Num. Publicaciones |
|---|---|
| Richard J. Auchus | 7 |
| Alyamani M. | 5 |
| Sharifi N. | 5 |
| Li Z. | 4 |
| Garcia J. | 2 |
| Berk M.P. | 2 |
| Li J. | 2 |
| Bratoeff E. | 1 |
| Peng H.M. | 1 |
| Garrido M. | 1 |
Cargando gráfico
Top Keywords
Cargando gráfico
Publicaciones del autor
A-ring modified steroidal azoles retaining similar potent and slowly reversible CYP17A1 inhibition as abiraterone
ArticleAbstract: Abiraterone acetate is a potent inhibitor of human cytochrome P450c17 (CYP17A1, 17α-hydroxylase/17,2Palabras claves:abiraterone, androgen, CYP17A1, Cytochrome p450, Enzymology, Prostate cancer, steroidogenesisAutores:Bratoeff E., Garrido M., Peng H.M., Richard J. Auchus, Upadhyay S.K., Yoshimoto F.K.Fuentes:scopusDevelopment and validation of a novel LC–MS/MS method for simultaneous determination of abiraterone and its seven steroidal metabolites in human serum: Innovation in separation of diastereoisomers without use of a chiral column
ArticleAbstract: Abiraterone acetate (AA), the prodrug of abiraterone, is FDA-approved for the treatment of castratioPalabras claves:abiraterone, LC–MS/MS, Metabolites, Method validation, Prostate cancerAutores:Alyamani M., Anderson D., Li Z., Richard J. Auchus, Sharifi N., Upadhyay S.K.Fuentes:scopusSteroidogenic Metabolism of Galeterone Reveals a Diversity of Biochemical Activities
ArticleAbstract: Galeterone is a steroidal CYP17A1 inhibitor, androgen receptor (AR) antagonist, and AR degrader, undPalabras claves:3βHSD, abiraterone, Androgens, CYP17A1, galeterone, metabolism, Prostate cancer, steroidsAutores:Alyamani M., Berk M.P., Li J., Li Z., Richard J. Auchus, Sharifi N., Tang J., Upadhyay S.K.Fuentes:scopusAdrenal-derived 11-oxygenated 19-carbon steroids are the dominant androgens in classic 21-hydroxylase deficiency
ArticleAbstract: Objective: To comprehensively characterize androgens and androgen precursors in classic 21-hydroxylaPalabras claves:Autores:Chomic R., Giordano T.J., Merke D.P., Nanba A.T., Rainey W.E., Richard J. Auchus, Shields J.J., Turcu A.F., Upadhyay S.K.Fuentes:scopusConversion of abiraterone to D4A drives anti-tumour activity in prostate cancer
ArticleAbstract: Prostate cancer resistance to castration occurs because tumours acquire the metabolic capability ofPalabras claves:Autores:Alyamani M., Bishop A., Bunch D., Dreicer R., Garcia J., Li Z., Liu J., Richard J. Auchus, Sharifi N., Upadhyay S.K.Fuentes:scopus